{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Liu Y"],"pubmed_abstract":["Limited real-world data are available regarding treatment practices and outcomes of multiple myeloma (MM) in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Taiwan Death Registry and used a Markov model to describe disease progression and outcomes in 4092 patients newly diagnosed with MM from 01-Jan-2007 to 31-Dec-2015. We observed marked differences in the characteristics, length and outcome of the clinical journey between patients who did/did not receive autologous stem cell transplant, and between patients initiated on novel agents versus other treatment regimens. In transplant recipients, initiation with combined thalidomide + bortezomib increased over time (12.2-77.5%). Progression-free survival after first-line trea"],"journal":["Scientific reports"],"pagination":["1112"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7806818"],"repository":["biostudies-literature"],"pubmed_title":["Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan."],"pmcid":["PMC7806818"],"pubmed_authors":["Siggins S","Liu Y","Tang CH","Qiu H","Hou HA"],"additional_accession":[]},"is_claimable":false,"name":"Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.","description":"Limited real-world data are available regarding treatment practices and outcomes of multiple myeloma (MM) in Asia. We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database and Taiwan Death Registry and used a Markov model to describe disease progression and outcomes in 4092 patients newly diagnosed with MM from 01-Jan-2007 to 31-Dec-2015. We observed marked differences in the characteristics, length and outcome of the clinical journey between patients who did/did not receive autologous stem cell transplant, and between patients initiated on novel agents versus other treatment regimens. In transplant recipients, initiation with combined thalidomide + bortezomib increased over time (12.2-77.5%). Progression-free survival after first-line trea","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-18T17:03:38.601Z","creation":"2021-02-20T23:27:25Z"},"accession":"S-EPMC7806818","cross_references":{"pubmed":["33441901"],"doi":["10.1038/s41598-020-80607-4"]}}